Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Advanced Micro Devices -- Ignore unavailable to you. Want to Upgrade?

To: Daniel Schuh who wrote (131056)	1/30/2001 11:20:02 AM
From: TimF	Read Replies (2) \| Respond to of 1571911

But not if the drug companies have anything to say about it. This article gets into the rather odd economics by which US companies charge extortionist rates on drugs that were often developed using government money, That may or may not be true when dealing with AIDS drugs, but most drug development money in general is not from the government. Brazil can afford to treat AIDS because it does not pay market prices for antiretroviral drugs -- the most controversial aspect of the country's plan. In 1998, the government began making copies of brand-name drugs, and the price of those medicines has fallen by an average of 79 percent. If Brazil does this it might work because drug companies will still develop drugs for the larger markets like the US. If the US and other rich countries start doing this you will not see as many new drugs developed. Tim